We have identified a list of several healthtech stocks that appear to be trending by receiving buy ratings from top Wall Street analysts and showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding {Name} to our watchlist to see if this momentum continues.
Summary: Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States.
- Recent Price: $$186.39
- Yearly Gain: 8.13%
- Market Cap: $5.14B
- P/E Ratio: -119.965
TipRanks.com reports that Inspire Medical Systems currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $282.50. The target pricing ranges from a high forecast of $310.00 down to a low forecast of $250.00. Inspire Medical Systems (INSP)’s last closing price was $$186.39 which would put the average price target at 51.56% upside.
In addition, TradingView issued a Sell rating for INSP over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on INSP.
Other analysts covering INSP include:
- Adam Maeder of Piper Sandler issued a Buy rating with the price target of $ 310 on 1 month ago
- Danielle Antalffy of SVB Securities issued a Buy rating with the price target of $ 300 on 1 month ago
- Michael Polark of Wolfe Research issued a Hold rating with the price target of $ 270 on 2 months ago
- Travis Steed of Bank of America Securities issued a Buy rating with the price target of $ 270 on 3 months ago
Here are 3rd party ratings for INSP:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 34% (166 out of 252)
What is the sentiment on the street regarding Inspire Medical Systems ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Neutral
- Blogger Consensus: Bullish
- Media Buzz: Very Low
- Insider Signal: Positive
- Investor Sentiment: Very Negative
- Hedge Fund signal: Very Positive
The stock market is extremely volatile, and you need to do your own research on INSP before you decide to make any investment.
Click here for INSP chart >>
Summary: Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
- Recent Price: $$3.72
- Yearly Gain: -81.84%
- Market Cap: $343.10M
- P/E Ratio: -3.845
TipRanks.com reports that Seres Therapeutics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.00. The target pricing ranges from a high forecast of $25.00 down to a low forecast of $7.00. Seres Therapeutics (MCRB)’s last closing price was $$3.72 which would put the average price target at 330.11% upside.
In addition, TradingView issued a Sell rating for MCRB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MCRB.
Other analysts covering MCRB include:
- Chris Howerton of Jefferies issued a Buy rating with the price target of n/a on 2 days ago
- Mark Breidenbach of Oppenheimer issued a Buy rating with the price target of n/a on 3 days ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 7 on 2 weeks ago
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of n/a on 1 month ago
Here are 3rd party ratings for MCRB:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 42% (105 out of 252)
What is the sentiment on the street regarding Seres Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bearish
- Media Buzz: Medium
- Insider Signal: ―
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
The stock market is extremely volatile, and you need to do your own research on MCRB before you decide to make any investment.
Click here for MCRB chart >>
Summary: PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.
- Recent Price: $$3.72
- Yearly Gain: -70.19%
- Market Cap: $105.84M
- P/E Ratio: -4.556
TipRanks.com reports that PDS Biotechnology currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $20.67. The target pricing ranges from a high forecast of $25.00 down to a low forecast of $15.00. PDS Biotechnology (PDSB)’s last closing price was $$3.72 which would put the average price target at 455.65% upside.
In addition, TradingView issued a Strong Sell rating for PDSB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on PDSB.
Other analysts covering PDSB include:
- Leland Gershell of Oppenheimer issued a Buy rating with the price target of $ 25 on 2 days ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 15 on 3 days ago
- James Molloy of Alliance Global Partners issued a Buy rating with the price target of n/a on 4 weeks ago
- Louise Chen of Cantor Fitzgerald issued a Buy rating with the price target of $ 25 on 9 months ago
Here are 3rd party ratings for PDSB:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 42% (105 out of 252)
What is the sentiment on the street regarding PDS Biotechnology ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Low
- Insider Signal: ―
- Investor Sentiment: Negative
- Hedge Fund signal: Neutral
The stock market is extremely volatile, and you need to do your own research on PDSB before you decide to make any investment.
Click here for PDSB chart >>
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
- Recent Price: $$3.86
- Yearly Gain: -72.16%
- Market Cap: $225.04M
- P/E Ratio: -3.162
TipRanks.com reports that Aldeyra Therapeutics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $23.75. The target pricing ranges from a high forecast of $29.00 down to a low forecast of $14.00. Aldeyra Therapeutics (ALDX)’s last closing price was $$3.86 which would put the average price target at 515.28% upside.
In addition, TradingView issued a Buy rating for ALDX over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALDX.
Other analysts covering ALDX include:
- Matthew Cross of Alliance Global Partners issued a Buy rating with the price target of $ 24 on 2 days ago
- Matthew Caufield of H.C. Wainwright issued a Buy rating with the price target of n/a on 2 days ago
- Marc Goodman of SVB Securities issued a Buy rating with the price target of n/a on 2 weeks ago
- Thomas Shrader of BTIG issued a Buy rating with the price target of $ 29 on 2 weeks ago
Here are 3rd party ratings for ALDX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 43% (144 out of 252)
What is the sentiment on the street regarding Aldeyra Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Neutral
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: ―
- Investor Sentiment: Negative
- Hedge Fund signal: Neutral
The stock market is extremely volatile, and you need to do your own research on ALDX before you decide to make any investment.
Click here for ALDX chart >>
Summary: Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
- Recent Price: $$12.49
- Yearly Gain: 6.52%
- Market Cap: $244.68M
- P/E Ratio: -10.894
TipRanks.com reports that Adicet Bio currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.86. The target pricing ranges from a high forecast of $35.00 down to a low forecast of $21.00. Adicet Bio (ACET)’s last closing price was $$12.49 which would put the average price target at 131.06% upside.
In addition, TradingView issued a Neutral rating for ACET over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ACET.
Other analysts covering ACET include:
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $ 21 on 3 days ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $ 35 on 3 days ago
- Justin Zelin of BTIG issued a Buy rating with the price target of $ 34 on 4 days ago
- Kelly Shi of Jefferies issued a Buy rating with the price target of $ 27 on 1 month ago
Here are 3rd party ratings for ACET:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 42% (105 out of 252)
What is the sentiment on the street regarding Adicet Bio ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: ―
- Media Buzz: Medium
- Insider Signal: ―
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
The stock market is extremely volatile, and you need to do your own research on ACET before you decide to make any investment.
Click here for ACET chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
